Login to Your Account

CAT, OGS Merger Could Trigger Consolidation In Biotech Sector

By Nuala Moran

Wednesday, January 29, 2003
The long-called-for restructuring of the UK biotech sector looked to have taken a major step last week when Cambridge Antibody Technology Group plc said it would acquire Oxford GlycoSciences plc in an all-share deal valuing OGS at £109.6 million (US$179.8 million). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription